```html

Kernicterus: A Complete Guide for Parents and Caregivers

What is Kernicterus?

Kernicterus is a rare but serious form of brain damage that can occur in newborn infants who have very high levels of bilirubin in the blood (a condition known as severe hyperbilirubinemia). Bilirubin is a yellow pigment produced when the body breaks down old red blood cells. In newborns, the liver is often immature and may not be able to process bilirubin efficiently, allowing it to accumulate. When bilirubin crosses the blood‑brain barrier, it can deposit in deep brain structures (particularly the basal ganglia and brainstem), leading to permanent neurological injury.

Historically, kernotinous was more common before the widespread use of phototherapy and aggressive monitoring of newborn jaundice. Today, it remains a medical emergency because the damage is often irreversible, but it is largely preventable with early detection and treatment of high bilirubin levels.

Sources: Mayo Clinic; American Academy of Pediatrics (AAP) guidelines; WHO.

Common Causes

Most cases of kernicterus stem from conditions that cause excessive bilirubin production or impaired elimination. The following are the most frequently encountered causes:

• Hemolytic disease of the newborn (HDN) – maternal‑fetal blood group incompatibility (e.g., Rh or ABO) leading to rapid red‑cell breakdown.
• Physiologic jaundice – the normal, transient rise in bilirubin that many newborns experience; risk increases with premature birth.
• Breast‑feeding jaundice – insufficient milk intake in the first days of life causing dehydration and reduced bilirubin excretion.
• Breast‑milk jaundice – substances in breast milk that interfere with bilirubin metabolism, typically presenting after the first week.
• Genetic enzyme deficiencies – e.g., glucose‑6‑phosphate dehydrogenase (G6PD) deficiency, pyruvate kinase deficiency, or Crigler‑Najjar syndrome.
• Prematurity – immature liver enzymes, increased red‑cell turnover, and low albumin levels all contribute to higher bilirubin.
• Infection – sepsis or congenital infections (CMV, rubella) can increase hemolysis and impair bilirubin conjugation.
• Metabolic disorders – e.g., hypothyroidism or galactosemia that affect bilirubin processing.
• Medications and toxins – certain drugs (e.g., sulfonamides, aspirin) or exposure to lead can increase bilirubin.
• Obstructive biliary disease – rare in neonates but includes conditions like biliary atresia.

Associated Symptoms

Early signs of dangerous hyperbilirubinemia may be subtle, but when bilirubin begins to affect the brain, the following symptoms often appear:

• Yellowing of the skin and eyes (jaundice) that spreads from the face to the trunk and limbs.
• Lethargy or poor feeding – the infant may be unusually sleepy or difficult to awaken.
• High‑pitched crying – a cry that sounds strained or shrill.
• Hypotonia – reduced muscle tone, leading to a “floppy” appearance.
• Movement abnormalities – involuntary jerking (chorea) or a characteristic “wing‑wing” arm position.
• Auditory dysfunction – reduced response to sounds, later progressing to permanent hearing loss.
• Seizures – may be focal or generalized and can be resistant to routine antiepileptic drugs.
• Eye‑movement abnormalities – upward gaze palsy or nystagmus.

Because many of these signs overlap with normal newborn behavior, routine bilirubin screening is essential.

When to See a Doctor

Prompt medical evaluation is crucial whenever a newborn shows any of the following:

• Jaundice that extends to the chest, abdomen, or legs (particularly if it appears within the first 24 hours after birth).
• A yellow color that does not fade with feeding or sunlight exposure.
• Feeding difficulties, vomiting, or an infant who is difficult to wake.
• Any change in the infant’s level of alertness, tone, or muscle movements.
• A family history of hemolytic disease, G6PD deficiency, or previous newborn jaundice complications.

If any of these occur, seek pediatric care immediately—most hospitals have protocols for rapid bilirubin measurement and treatment.

Diagnosis

Evaluation of suspected kernicterus follows a stepwise approach:

1. Clinical assessment

• Physical exam focusing on the extent of jaundice, neurological status, and hydration.
• Documentation of feeding patterns and weight changes.

2. Laboratory tests

• Serum total bilirubin (TB) level – measured via a heel‑stick or venous sample; levels >20 mg/dL (≈340 µmol/L) in term infants are concerning, but thresholds vary with age and risk factors.
• Direct (conjugated) bilirubin – helps differentiate hemolytic from obstructive jaundice.
• Complete blood count, reticulocyte count, and blood type to assess hemolysis.
• G6PD assay, thyroid panel, or metabolic screens if indicated.

3. Imaging & neuro‑assessment

• Transcranial ultrasound or MRI – may reveal kernicterus‑related changes (e.g., T1‑weighted hyperintensity in the basal ganglia).
• Auditory brain‑stem response (ABR) testing to evaluate early hearing loss.

4. Risk‑assessment tools

Clinicians often use the American Academy of Pediatrics (AAP) bilirubin nomogram which plots the infant’s age in hours against the measured bilirubin to decide on treatment urgency.

Treatment Options

Therapy aims to rapidly lower serum bilirubin and prevent further brain exposure.

Phototherapy

• First‑line treatment for most newborns with bilirubin >15 mg/dL (≈255 µmol/L) or lower if risk factors exist.
• Blue‑light (≈460 nm) converts bilirubin into water‑soluble isomers that can be excreted without conjugation.
• Intensive (double‑surface) phototherapy may be required for rapid reduction.

Exchange Transfusion

• Indicated when bilirubin exceeds critical levels (≈20–25 mg/dL in term infants) despite maximal phototherapy, or when neuro‑symptoms appear.
• Blood is removed and replaced with donor plasma, lowering bilirubin and circulating antibodies.
• Requires a NICU setting, experienced staff, and careful monitoring for electrolyte shifts, hemolysis, or infection.

Adjunctive Measures

• IVIG (intravenous immunoglobulin) – used in hemolytic disease due to ABO or Rh incompatibility to reduce hemolysis.
• Hydration and feeding support – frequent breastfeeding or formula supplementation to promote bilirubin excretion.
• Albumin infusion – in rare cases to bind free bilirubin when albumin levels are low.

Long‑term Management for Survivors

• Physical, occupational, and speech therapy to address motor and developmental delays.
• Regular audiology follow‑up; many children need hearing aids.
• Neurology and developmental pediatrics follow‑up for seizure control and cognitive support.

Prevention Tips

Because kernicterus is largely preventable, the best strategy is early detection and management of jaundice:

• Routine bilirubin screening – most hospitals obtain a transcutaneous bilirubin measurement before discharge (typically at 24 hours).
• Frequent feeding – aim for 8–12 feedings per 24 hours to promote stool output and bilirubin elimination.
• Monitor weight – a loss >5‑7 % of birth weight is a red flag for dehydration.
• Educate caregivers – teach parents how to recognize early jaundice (yellowing of the face and upper chest) and when to call the pediatrician.
• Early follow‑up – schedule a check‑up within 48 hours after discharge for infants at risk (premature, ABO/Rh incompatibility, G6PD deficiency).
• Breast‑feeding support – lactation consultants can help resolve latch issues that may lead to inadequate intake.
• Avoid high‑risk medications – certain drugs (e.g., sulfonamides, chloramphenicol) should be avoided in newborns unless absolutely necessary.
• For infants with known hemolytic disease, consider prophylactic IVIG or early phototherapy as recommended by the neonatology team.

Emergency Warning Signs

---

© 2026 HealthBridge Symptom Checker. All information provided is for educational purposes and does not replace professional medical advice. If you have concerns about your or your child’s health, consult a qualified healthcare provider.

```